Table 5.

Actual counts using optimal cut points

Treatment	Status	Actual # with no meaningful benefit	Actual # with neither actionable outcome	Actual # remitters
Bupropion + escitalopram	# Predicted with no meaningful benefit	9	2	0
	# predicted neither	35	74	60
	# predicted remitters	1	3	22
	Totals	45	79	82
Escitalopram + PBO	# Predicted with no meaningful benefit	9	3	1
	# predicted neither	33	71	51
	# predicted remitters	4	7	33
	Totals	46	81	85

Notes: “No meaningful benefit” assigned when patients saw less than a 30% decrease in QIDS-SR₁₆ score from baseline to exit. “Remission” assigned when QIDS-SR₁₆ scores during the last 2 weeks were below 8 in 1 week and below 6 in the other week. “Neither” assigned when criteria for substantial non-response and remission not met.

Abbreviation: PBO, placebo.